Applied Proteomics

The API assets could enable more data-intensive, machine learning-based approaches to healthcare, said a principal at DiscernDx investor Khosla Ventures.

DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.

The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.

The test, which the company aims to launch in the next few months, offers a boost in specificity compared to its existing SimpliPro Colon proteomic test.

Company officials said that they have seen favorable reorder rates and coverage decisions since launching the 11-protein colorectal cancer test in late 2015.

While the company had previously planned to launch on mass spec, it is using ELISA for the initial version of the test in a bid to bring it to market more quickly.

NEW YORK (GenomeWeb News) – Applied Proteomics today said that it will collaborate with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) on the discovery and development of molecular diagnostic tests for colon and pancreatic cancer.

Applied Proteomics said this week that it has closed a $28 million Series C financing round.

Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group.

NEW YORK (GenomeWeb News) – Applied Proteomics said today that it has closed a $28 million Series C financing round.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.